AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aura Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.29+0.19 (+3.11%)
Close on Oct 19, 2026
- Market cap
- $596.69M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
94.8%
98M of 104M shares
Institutional holders
146
37 new, 15 sold out
Net institutional buying
47M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $39.98M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Chen Yu | 9,533,333 | 9.90% | 13G (passive) | May 5, 2026 |
| Robert Atchinson | 9,104,294 | 8.44% | 13G (passive) amendment | Jun 30, 2026 |
| Matrix Capital Management Company LP | 6,922,870 | 11.17% | 13D (active) amendment | May 16, 2025 |
| Patrick J. Heron | 6,315,678 | 9.90% | 13G (passive) | May 16, 2025 |
| Frazier Life Sciences Public Fund, L.P. | 5,807,260 | 5.60% | 13G (passive) amendment | Jun 30, 2026 |
| ForGrowth III PA B.V. | 5,248,841 | 5.10% | 13G (passive) | Sep 25, 2026 |
| Suvretta Capital Management, LLC | 4,701,775 | 7.60% | 13G (passive) amendment | Jun 30, 2025 |
| Adage Capital Partners GP, L.L.C. | 4,225,000 | 8.61% | 13G (passive) amendment | Dec 31, 2023 |
| Fhmlsp, L.P. | 4,032,060 | 6.30% | 13G (passive) amendment | Dec 31, 2025 |
| Long Focus Capital Management, LLC | 3,319,582 | 6.60% | 13G (passive) amendment | Mar 31, 2025 |
| Fhmlsp, L.L.C. | 3,113,550 | 5.00% | 13G (passive) amendment | Jun 30, 2025 |
| Aaron Cowen | 3,057,319 | 6.10% | 13G (passive) | Apr 4, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AURA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9,533,333 | 9.19% | $67.69M | New | 1.63% |
| Suvretta Capital Management, LLC | 7,206,217 | 6.95% | $51.16M | +2,833,333 | 0.94% |
| Frazier Life Sciences Management, L.P. | 7,100,000 | 6.85% | $50.41M | +2,000,000 | 1.10% |
| Nantahala Capital Management, LLC | 5,902,060 | 5.69% | $41.90M | +3,784,363 | 0.70% |
| Long Focus Capital Management, LLC | 5,119,582 | 4.94% | $36.35M | +500,000 | 0.93% |
| BlackRock, Inc. | 4,707,674 | 4.54% | $33.42M | +1,121,034 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 4,640,000 | 4.47% | $32.94M | −241,125 | 0.05% |
| Caligan Partners LP | 4,298,248 | 4.14% | $30.52M | +4,068,384 | 1.44% |
| Vanguard Capital Management LLC | 4,100,342 | 3.95% | $29.11M | +1,856,514 | 0.00% |
| Fcpm Iii Services B.V. | 4,053,775 | 3.91% | $28.78M | New | 3.84% |
| Orbimed Advisors LLC | 3,333,333 | 3.21% | $23.67M | New | 0.44% |
| Medicxi Ventures Management (Jersey) Ltd | 3,039,892 | 2.93% | $21.58M | – | 12.16% |
| Jupiter Topco LLC | 2,500,000 | 2.41% | $17.79M | New | 0.01% |
| Ra Capital Management, L.P. | 2,500,000 | 2.41% | $17.75M | New | 0.15% |
| Balyasny Asset Management L.P. | 2,354,619 | 2.27% | $16.72M | +1,796,965 | 0.02% |
| Franklin Resources Inc | 2,072,726 | 2.00% | $14.72M | – | 0.00% |
| Geode Capital Management, LLC | 1,754,721 | 1.69% | $12.46M | +443,859 | 0.00% |
| Redmile Group, LLC | 1,666,667 | 1.61% | $11.83M | New | 0.79% |
| EcoR1 Capital, LLC | 1,666,667 | 1.61% | $11.83M | New | 0.58% |
| Trails Edge Capital Partners, LP | 1,443,333 | 1.39% | $10.25M | New | 1.63% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 146 | 98M | 94.8% | 37 / 58 | 27 / 15 | 56M | 8M |
| Q1 2026 | 126 | 51M | 49.1% | 23 / 39 | 41 / 12 | 5M | 1M |
| Q4 2025 | 117 | 50M | 48.4% | 19 / 34 | 38 / 8 | 1M | 3M |
| Q3 2025 | 106 | 52M | 49.8% | 15 / 34 | 26 / 13 | 2M | 1M |
| Q2 2025 | 104 | 51M | 48.8% | 26 / 32 | 30 / 15 | 12M | 1M |
| Q1 2025 | 94 | 40M | 38.4% | 15 / 31 | 29 / 14 | 5M | 5M |
| Q4 2024 | 94 | 39M | 38.0% | 22 / 38 | 16 / 9 | 5M | 2M |
| Q3 2024 | 81 | 37M | 35.6% | 11 / 30 | 25 / 3 | 4M | 5M |
| Q2 2024 | 75 | 41M | 39.6% | 12 / 35 | 19 / 15 | 4M | 3M |
| Q1 2024 | 78 | 39M | 37.9% | 13 / 34 | 19 / 7 | 3M | 2M |
| Q4 2023 | 72 | 38M | 37.0% | 16 / 37 | 10 / 7 | 13M | 1M |
| Q3 2023 | 64 | 27M | 26.5% | 6 / 26 | 19 / 1 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AURA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,902,292 | 2.80% | $20.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,171,191 | 1.13% | $8.32M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,108,212 | 1.07% | $7.87M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 765,617 | 0.74% | $5.37M | 0.46% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 502,397 | 0.48% | $3.75M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 488,920 | 0.47% | $3.43M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 455,972 | 0.44% | $3.24M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 394,396 | 0.38% | $2.80M | 0.02% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 279,337 | 0.27% | $2.09M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 231,086 | 0.22% | $1.73M | 0.01% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 196,067 | 0.19% | $1.39M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 187,048 | 0.18% | $1.31M | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 183,089 | 0.18% | $1.37M | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 181,359 | 0.17% | $1.29M | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 174,907 | 0.17% | $1.23M | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Natalie C. Holles | See Remarks, Director | 600,118 | 0.58% | May 19, 2026 |
| los Pinos Elisabet de | See Remarks, Director | 703,578 | 0.68% | Mar 3, 2026 |
| Julie Person | Chief People Officer | 107,611 | 0.10% | Sep 1, 2026 |
| Susan Abu-Absi | Chief Operating Officer | 134,513 | 0.13% | Sep 1, 2026 |
| Janet Jill Hopkins | Chief Medical Officer | 380,190 | 0.37% | Sep 1, 2026 |
| Erica Kratz | Chief Reg. & Quality Officer | 100,885 | 0.10% | Sep 1, 2026 |
| Amy Elazzouzi | SVP, Finance & PAO | 143,600 | 0.14% | Sep 1, 2026 |
| Conor Kilroy | See Remarks | 232,693 | 0.22% | Jul 1, 2026 |
| Anthony S. Gibney | See Remarks | 265,354 | 0.26% | Jun 16, 2026 |
| Mark Plavsic | Chief Technology Officer | 243,736 | 0.24% | Mar 3, 2026 |
| Jeremy Bender | Director | 30,000 | 0.03% | Jul 8, 2026 |
| Sapna Srivastava | Director | 38,500 | 0.04% | Jun 15, 2026 |
| Teresa Marie Bitetti | Director | 36,000 | 0.03% | Jun 15, 2026 |
| Antony C. Mattessich | Director | 38,500 | 0.04% | Jun 15, 2026 |
| David Michael Johnson | Director | 483,839 | 0.47% | Jun 15, 2026 |
| Matrix Capital Management Company, LP | 10% owner | 0 | – | May 11, 2026 |
| David E. Goel | 10% owner | 4,112,870 | 3.97% | May 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Erica Kratz Chief Reg. & Quality Officer | Sep 1, 2026 | Award | +100,885 | – | – | 100,885 |
| Janet Jill Hopkins Chief Medical Officer | Sep 1, 2026 | Award | +58,850 | – | – | 380,190 |
| Susan Abu-Absi Chief Operating Officer | Sep 1, 2026 | Award | +134,513 | – | – | 134,513 |
| Julie Person Chief People Officer | Sep 1, 2026 | Award | +107,611 | – | – | 107,611 |
| Amy Elazzouzi SVP, Finance & PAO | Sep 1, 2026 | Award | +23,540 | – | – | 143,600 |
| Jeremy Bender Director | Jul 7, 2026 | Award | +30,000 | – | – | 30,000 |
| Conor Kilroy See Remarks | Jul 1, 2026 | Award | +14,858 | – | – | 232,693 |
| Anthony S. Gibney See Remarks | Jun 16, 2026 | Sale | −12,824 | $6.42 | $82.33K | 265,354 |
| Teresa Marie Bitetti Director | Jun 11, 2026 | Award | +15,000 | – | – | 36,000 |
| Antony C. Mattessich Director | Jun 11, 2026 | Award | +15,000 | – | – | 38,500 |
| David Michael Johnson Director | Jun 11, 2026 | Award | +15,000 | – | – | 194,167 |
| Sapna Srivastava Director | Jun 11, 2026 | Award | +15,000 | – | – | 38,500 |
| Natalie C. Holles See Remarks, Director | May 19, 2026 | Award | +600,118 | – | – | 600,118 |
| Natalie C. Holles See Remarks, Director | May 19, 2026 | Award | +553,844 | – | – | 1,153,962 |
| Matrix Capital Management Company, LP 10% owner | May 7, 2026 | Sale | −6,922,870 | $5.64 | $39.04M | 0 |
| Conor Kilroy See Remarks | Apr 16, 2026 | Sale | −11,738 | $7.02 | $82.40K | 217,835 |
| Conor Kilroy See Remarks | Mar 2, 2026 | Award | +62,339 | – | – | 229,573 |
| los Pinos Elisabet de See Remarks, Director | Mar 2, 2026 | Award | +166,000 | – | – | 575,815 |
| Mark Plavsic Chief Technology Officer | Mar 2, 2026 | Award | +62,339 | – | – | 243,736 |
| Janet Jill Hopkins Chief Medical Officer | Mar 2, 2026 | Award | +89,056 | – | – | 321,340 |
| Anthony S. Gibney See Remarks | Mar 2, 2026 | Award | +71,245 | – | – | 278,178 |
| Amy Elazzouzi Senior Vice President, Finance | Mar 2, 2026 | Award | +44,528 | – | – | 120,060 |
| los Pinos Elisabet de See Remarks, Director | Feb 17, 2026 | Sale | −47,648 | $5.06 | $241.10K | 409,815 |
| Conor Kilroy See Remarks | Feb 17, 2026 | Sale | −12,079 | $5.05 | $61.00K | 167,234 |
| Amy Elazzouzi Senior Vice President, Finance | Feb 17, 2026 | Sale | −8,549 | $5.06 | $43.26K | 75,532 |
| Janet Jill Hopkins Chief Medical Officer | Feb 17, 2026 | Sale | −20,401 | $5.06 | $103.23K | 232,284 |
| Mark Plavsic Chief Technology Officer | Feb 17, 2026 | Sale | −15,890 | $5.05 | $80.24K | 181,397 |
| los Pinos Elisabet de See Remarks, Director | Jan 20, 2026 | Sale | −16,928 | $4.86 | $82.27K | 457,463 |
| Amy Elazzouzi Senior Vice President, Finance | Jan 20, 2026 | Sale | −1,581 | $4.86 | $7.68K | 84,081 |
| Janet Jill Hopkins Chief Medical Officer | Nov 17, 2025 | Sale | −17,109 | $5.42 | $92.73K | 252,685 |
| Amy Elazzouzi Senior Vice President, Finance | Oct 29, 2025 | Sale | −896 | $6.35 | $5.69K | 85,662 |
| los Pinos Elisabet de See Remarks, Director | Oct 29, 2025 | Sale | −9,049 | $6.35 | $57.46K | 474,391 |
| Mark Plavsic Chief Technology Officer | Oct 16, 2025 | Sale | −12,169 | $6.35 | $77.27K | 197,287 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +1,094 | $3.16 | $3.46K | 91,961 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +2,554 | $5.07 | $12.95K | 83,935 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Sale | −7,722 | $6.70 | $51.74K | 86,558 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +4,744 | $2.74 | $13.00K | 90,867 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +547 | $5.48 | $3.00K | 85,576 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +547 | $5.21 | $2.85K | 86,123 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +1,094 | $5.48 | $6.00K | 85,029 |
| Amy Elazzouzi Senior Vice President, Finance | Aug 18, 2025 | Option exercise | +2,319 | $4.25 | $9.86K | 94,280 |
| Antony C. Mattessich Director | Jun 17, 2025 | Award | +13,000 | – | – | 23,500 |
| David Michael Johnson Director | Jun 17, 2025 | Award | +13,000 | – | – | 179,167 |
| Sapna Srivastava Director | Jun 17, 2025 | Award | +13,000 | – | – | 23,500 |
| los Pinos Elisabet de See Remarks, Director | Jun 2, 2025 | Tax withholding | −9,948 | $6.16 | $61.28K | 483,440 |
| los Pinos Elisabet de See Remarks, Director | Jun 2, 2025 | Option exercise | +10,948 | $5.07 | $55.51K | 493,388 |
| Anthony S. Gibney See Remarks | Jun 2, 2025 | Award | +150,000 | – | – | 206,933 |
| David Michael Johnson Director | May 16, 2025 | Buy | +20,000 | $4.90 | $98.00K | 166,167 |
| Anthony S. Gibney See Remarks | May 16, 2025 | Sale | −1,519 | $5.15 | $7.82K | 56,933 |
| Anthony S. Gibney See Remarks | May 16, 2025 | Buy | +50,000 | $4.90 | $245.00K | 58,452 |
| Amy Elazzouzi Senior Vice President, Finance | Apr 16, 2025 | Sale | −897 | $5.49 | $4.92K | 81,381 |
| Conor Kilroy See Remarks | Apr 16, 2025 | Sale | −7,162 | $5.49 | $39.32K | 179,313 |
| Teresa Marie Bitetti Director | Mar 31, 2025 | Award | +21,000 | – | – | 21,000 |
| Amy Elazzouzi Senior Vice President, Finance | Feb 18, 2025 | Sale | −1,404 | $7.75 | $10.88K | 82,278 |
| los Pinos Elisabet de See Remarks, Director | Feb 18, 2025 | Sale | −20,221 | $7.75 | $156.71K | 482,440 |
| Mark Plavsic Chief Technology Officer | Feb 18, 2025 | Sale | −2,151 | $7.75 | $16.67K | 209,456 |
| Janet Jill Hopkins Chief Medical Officer | Feb 18, 2025 | Sale | −2,534 | $7.75 | $19.64K | 269,794 |
| Amy Elazzouzi Senior Vice President, Finance | Feb 3, 2025 | Award | +45,240 | – | – | 83,682 |
| Mark Plavsic Chief Technology Officer | Feb 3, 2025 | Award | +90,475 | – | – | 211,607 |
| Janet Jill Hopkins Chief Medical Officer | Feb 3, 2025 | Award | +120,635 | – | – | 272,328 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Anthony Gibney Officer | Jun 16, 2026 | 12,824 | $82.33K | Jun 16, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Conor Kilroy Officer | Apr 16, 2026 | 11,738 | $82.40K | Apr 16, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Mark Plavsic Officer | Feb 17, 2026 | 15,890 | $80.27K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Conor Kilroy Officer | Feb 17, 2026 | 12,079 | $61.04K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Janet Jill Hopkins Officer | Feb 17, 2026 | 20,401 | $103.23K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| los Pinos Elisabet de Officer, Director | Feb 17, 2026 | 47,648 | $241.06K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Amy Elazzouzi Officer | Feb 17, 2026 | 8,549 | $43.26K | Feb 17, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Amy Elazzouzi Officer | Jan 20, 2026 | 1,581 | $7.68K | Jan 20, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| los Pinos Elisabet de Officer, Director | Jan 20, 2026 | 16,928 | $82.23K | Jan 20, 2026 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Janet Jill Hopkins Officer | Nov 17, 2025 | 17,109 | $92.73K | Nov 17, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Amy Elazzouzi Officer | Oct 29, 2025 | 896 | $5.69K | Oct 29, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| los Pinos Elisabet de Officer, Director | Oct 29, 2025 | 9,049 | $57.46K | Oct 29, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| Mark Plavsic Officer | Oct 16, 2025 | 12,169 | $77.27K | Oct 16, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |
| F. Elazzouzi Amy Officer | Aug 18, 2025 | 7,722 | $51.75K | Aug 18, 2025 | Stock Option Exercise |
| Anthony Gibney Officer | May 16, 2025 | 1,519 | $7.82K | May 16, 2025 | Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements. |